These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24918788)

  • 1. The impact of weight loss on weight-related quality of life and health satisfaction: results from a trial comparing canagliflozin with sitagliptin in triple therapy among people with type 2 diabetes.
    Traina S; Guthrie R; Slee A
    Postgrad Med; 2014 May; 126(3):7-15. PubMed ID: 24918788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attainment of diabetes-related quality measures with canagliflozin versus sitagliptin.
    Bailey RA; Damaraju CV; Martin SC; Meininger GE; Rupnow MF; Blonde L
    Am J Manag Care; 2014 Jan; 20(1 Suppl):s16-24. PubMed ID: 24512193
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes-related quality measure attainment: canagliflozin versus sitagliptin based on a pooled analysis of 2 clinical trials.
    Bailey RA; Vijapurkar U; Meininger GE; Rupnow MF; Blonde L
    Am J Manag Care; 2014 Dec; 20(13 Suppl):s296-305. PubMed ID: 25734218
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.
    Forst T; Guthrie R; Goldenberg R; Yee J; Vijapurkar U; Meininger G; Stein P
    Diabetes Obes Metab; 2014 May; 16(5):467-77. PubMed ID: 24528605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
    Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
    Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Oral add-on therapy to metformin in type 2 diabetes mellitus: a direct comparison between canagliflozin and sitagliptin].
    Schnell O
    Dtsch Med Wochenschr; 2014 Feb; 139 Suppl 2():S70-4. PubMed ID: 24481636
    [No Abstract]   [Full Text] [Related]  

  • 8. Diabetes-Related Composite Quality End Point Attainment: Canagliflozin Versus Sitagliptin Based on a Pooled Analysis of 2 Clinical Trials.
    Bailey RA; Vijapurkar U; Meininger G; Rupnow MF; Blonde L
    Clin Ther; 2015 May; 37(5):1045-54. PubMed ID: 25795432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patient-reported outcomes in trials of incretin-based therapies in patients with type 2 diabetes mellitus.
    Davies M; Speight J
    Diabetes Obes Metab; 2012 Oct; 14(10):882-92. PubMed ID: 22420869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
    Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
    Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liraglutide improves treatment satisfaction in people with Type 2 diabetes compared with sitagliptin, each as an add on to metformin.
    Davies M; Pratley R; Hammer M; Thomsen AB; Cuddihy R
    Diabet Med; 2011 Mar; 28(3):333-7. PubMed ID: 21309842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Canagliflozin in Asian patients with type 2 diabetes on metformin alone or metformin in combination with sulphonylurea.
    Ji L; Han P; Liu Y; Yang G; Dieu Van NK; Vijapurkar U; Qiu R; Meininger G
    Diabetes Obes Metab; 2015 Jan; 17(1):23-31. PubMed ID: 25175734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of vulvovaginal symptoms and Candida colonization in women with type 2 diabetes mellitus treated with canagliflozin, a sodium glucose co-transporter 2 inhibitor.
    Nyirjesy P; Zhao Y; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1173-8. PubMed ID: 22632452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of Canagliflozin Treatment on Health-Related Quality of Life among People with Type 2 Diabetes Mellitus: A Pooled Analysis of Patient-Reported Outcomes from Randomized Controlled Trials.
    Cai J; Delahanty LM; Akapame S; Slee A; Traina S
    Patient; 2018 Jun; 11(3):341-352. PubMed ID: 29313267
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.
    Wilding JP; Charpentier G; Hollander P; González-Gálvez G; Mathieu C; Vercruysse F; Usiskin K; Law G; Black S; Canovatchel W; Meininger G
    Int J Clin Pract; 2013 Dec; 67(12):1267-82. PubMed ID: 24118688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study.
    Nicolle LE; Capuano G; Ways K; Usiskin K
    Curr Med Res Opin; 2012 Jul; 28(7):1167-71. PubMed ID: 22548646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of canagliflozin in patients with type 2 diabetes mellitus: pooled analysis of phase 3 study results.
    Usiskin K; Kline I; Fung A; Mayer C; Meininger G
    Postgrad Med; 2014 May; 126(3):16-34. PubMed ID: 24918789
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes.
    Rosenstock J; Aggarwal N; Polidori D; Zhao Y; Arbit D; Usiskin K; Capuano G; Canovatchel W;
    Diabetes Care; 2012 Jun; 35(6):1232-8. PubMed ID: 22492586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
    Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
    Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin is effective as add-on therapy to sitagliptin with or without metformin: a 24-week, multicenter, randomized, double-blind, placebo-controlled study.
    Jabbour SA; Hardy E; Sugg J; Parikh S;
    Diabetes Care; 2014; 37(3):740-50. PubMed ID: 24144654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.